

11TH ANNUAL MEETING OF THE LUPUS ACADEMY

Pre-Meeting Session: 25th March 2022

Hybrid Meeting: 8–10th April 2022

Catch-up Content available Online until 30th June 2022

www.lupus-academy.org

LUPUS ACADEMY 11TH ANNUAL MEETING

FRIDAY 25TH MARCH 2022

PRE-MEETING SESSION I: OLD DRUGS ON THE STAGE

CET (Paris, Amsterdam, Berlin) UTC +1: 14:00–16:00

Moderators: Zahir Amoura (France) & Thomas Dörner (Germany)

14:00	Glucocorticoids for SLE: What are the current questions and issues? <i>Q&A and Discussion (15 Mins)</i>	<i>Guillermo Ruiz-Irastorza (Spain)</i>
14:30	Cyclophosphamide: What is its role in the treatment of lupus nephritis and the new treatment paradigm? <i>Q&A and Discussion (15 Mins)</i>	<i>Liz Lightstone (UK)</i>
15:00	Top 10 tips regarding patient adherence to hydroxychloroquine <i>Q&A and Discussion (15 Mins)</i>	<i>Nathalie Costedoat-Chalumeau (France)</i>
15:30	Panel Discussion (30 Mins)	<i>All</i>
16:00	Close	

**LUPUS ACADEMY 11TH ANNUAL MEETING
FRIDAY 8TH APRIL 2022**

OPENING SESSION

(LIVE-STREAMED WITH EXTERNAL Q&A)

CEST (Paris, Amsterdam, Berlin) UTC +2: 13:30–15:45

Moderators: Eloisa Bonfá (Brazil) & Ronald van Vollenhoven (Netherlands)		
13:30	Opening Address	<i>Andrea Doria (Italy) & Eloisa Bonfá (Brazil)</i>
	Debate	
13:35	The matter of the debate: LLDAS is an excellent outcome measure, but does it really capture patients with true LDA? <i>(10 Mins)</i>	<i>Ronald van Vollenhoven (Netherlands)</i>
	YES <i>(20 Mins + 10 Mins Rebuttal)</i>	<i>Eric Morand (Australia)</i>
	NO <i>(20 Mins + 10 Mins Rebuttal)</i>	<i>Andrea Doria (Italy)</i>
	Voting, Q&A and Discussion (20 Mins)	All
Moderators: Andrea Doria (Italy) & Eloisa Bonfá (Brazil)		
	Keynote	
15:05	B cells as a therapeutic target in SLE: Where we are today and where we may be tomorrow <i>Q&A and Discussion (15 Mins)</i>	<i>Thomas Dörner (Germany)</i>
15:45	Break	

PLENARY I: CONTROVERSIAL ISSUES IN THE MANAGEMENT OF SLE

CEST (Paris, Amsterdam, Berlin) UTC +2: 16:15–18:15

Moderators: Andrea Doria (Italy) & Eloisa Bonfá (Brazil)		
16:15	Are DOACs dead? Or do they still have a role in SLE/APS? <i>Q&A and Discussion (15 Mins)</i>	<i>David Isenberg (UK)</i>
16:45	COVID-19 vaccine in lupus patients <i>Q&A and Discussion (15 Mins)</i>	<i>Eloisa Bonfá (Brazil)</i>
17:15	Novel concepts in SLE: Is it time for a new taxonomy? <i>Q&A and Discussion (15 Mins)</i>	<i>Ronald van Vollenhoven (Netherlands)</i>
17:45	Should PROs be incorporated in the response evaluation? <i>Q&A and Discussion (15 Mins)</i>	<i>Marta Mosca (Italy)</i>
18:15	Close Followed by Evening Networking	

**LUPUS ACADEMY 11TH ANNUAL MEETING
SATURDAY 9TH APRIL 2022**

CASE STUDY INTERACTIVE WORKSHOPS

CEST (Paris, Amsterdam, Berlin) UTC +2: 09:00–10:30

Moderator: Bernardo Pons-Estel (Argentina)		
09:00	Management of lupus skin manifestations	Annegret Kuhn (Germany) & Marzia Caproni (Italy)
Moderator: Andrea Doria (Italy)		
09:00	Management of lupus nephritis	Gabriella Moroni (Italy) & Richard Furie (USA)
Moderator: Murray Urowitz (Canada)		
09:00	Management of neuropsychiatric SLE	Dimitrios Boumpas (Greece) & Zahir Amoura (France)
Moderator: Thomas Dörner (Germany)		
09:00	Management of pregnancy in SLE and APS	Angela Tincani (Italy) & Jill Buyon (USA)
10:30	Break	

THIEVES' MARKET

CEST (Paris, Amsterdam, Berlin) UTC +2: 11:00–12:00

Moderators: Zahir Amoura (France) & Eloisa Bonfá (Brazil)		
11:00	Case in practice: Diaries from a long journey <i>Q&A and Discussion (10 Mins)</i>	Edoardo Marrani (Italy)
11:15	Case in practice: I´m becoming "Michelin Man" progressively <i>Q&A and Discussion (10 Mins)</i>	Carolina Aulestia (Ecuador)
11:30	Case in practice: When your mouth pops <i>Q&A and Discussion (10 Mins)</i>	Francisca Guimarães (Portugal)
11:45	Discussion and Awards	
12:00	Lunch	

PRIME TIME SESSION: TREATMENT TARGETS AND NOVEL THERAPIES

(Live-streamed WITH EXTERNAL Q&A)

CEST (Paris, Amsterdam, Berlin) UTC +2: 13:15–15:45

Moderators: Zahir Amoura (France) & Murray Urowitz (Canada)		
13:15	Cells involved in SLE: Beyond B cells <i>Q&A and Discussion (15 Mins)</i>	Anne Davidson (USA)
13:45	Cytokines involved in SLE: Beyond IFN <i>Q&A and Discussion (15 Mins)</i>	George Tsokos (USA)
14:15	New and approved therapies for SLE: Anifrolumab <i>Q&A and Discussion (15 Mins)</i>	Ronald van Vollenhoven (Netherlands)
14:45	New and approved therapies for LN: Belimumab and voclosporin <i>Q&A and Discussion (15 Mins)</i>	Richard Furie (USA)
15:15	Panel Discussion (30 Mins)	
15:45	Break	

CASE STUDY INTERACTIVE WORKSHOPS

CEST (Paris, Amsterdam, Berlin) UTC +2: 16:15–17:45

<i>Moderator: Bernardo Pons-Estel (Argentina)</i>		
16:15	Management of lupus skin manifestations	<i>Annegret Kuhn (Germany) & Marzia Caproni (Italy)</i>
<i>Moderator: Andrea Doria (Italy)</i>		
16:15	Management of lupus nephritis	<i>Gabriella Moroni (Italy) & Richard Furie (USA)</i>
<i>Moderator: Murray Urowitz (Canada)</i>		
16:15	Management of neuropsychiatric SLE	<i>Dimitrios Boumpas (Greece) & Zahir Amoura (France)</i>
<i>Moderator: Thomas Dörner (Germany)</i>		
16:15	Management of pregnancy in SLE and APS	<i>Angela Tincani (Italy) & Jill Buyon (USA)</i>
17:45	Close	

LUPUS ACADEMY 11TH ANNUAL MEETING

SUNDAY 10TH APRIL 2022

PLENARY II: CHALLENGES IN LUPUS

CEST (Paris, Amsterdam, Berlin) UTC +2: 08:30–10:30

<i>Moderators: Eloisa Bonfá (Brazil) & David Isenberg (UK)</i>		
08:30	Disease activity and treatment targets in SLE <i>Q&A and Discussion (10 Mins)</i>	<i>Luís Ines (Portugal)</i>
08:55	Molecular signatures in kidney biopsies and their relationship to clinical activity <i>Q&A and Discussion (10 Mins)</i>	<i>Jill Buyon (USA)</i>
09:20	What drives rapid progression to ESRD in patients with lupus nephritis? <i>Q&A and Discussion (10 Mins)</i>	<i>Murray Urowitz (Canada)</i>
09:45	Increased CV risk in women with SLE: Stories from a panel of biomarkers <i>Q&A and Discussion (10 Mins)</i>	<i>Matteo Piga (Italy)</i>
10:10	Panel Discussion (20 Mins)	
10:30	Break	

POSTER SESSION: PRESENTATIONS

CEST (PARIS, AMSTERDAM, BERLIN) UTC +2: 11:00–12:00

<i>Moderators: Andrea Doria (Italy) & Eloisa Bonfá (Brazil)</i>		
11:00	Adaptation and validation of the Systemic Lupus Erythematosus Quality of Life Questionnaire (L-QoL) for use in Bulgaria <i>Q&A (5 Mins)</i>	<i>Daliya Tsvetanova Pencheva (Bulgaria)</i>
11:10	Relationship of anti-double stranded DNA antibodies titers and echocardiographic parameters in systemic lupus erythematosus patients <i>Q&A (5 Mins)</i>	<i>Natalia Guajardo-Jauregui (Mexico)</i>
11:20	Patients with SLE have unique changes in serum metabolic profiles across age associated with cardiometabolic risk <i>Q&A (5 Mins)</i>	<i>George A Robinson (UK)</i>
11:30	Intercurrent infection as a risk factor for disease flares in patients with systemic lupus erythematosus	<i>Fatma el Hadiyen (The Netherlands)</i>

11:40	Transcriptome profiling and autoimmunity-related serological markers identify TP53 and C3aR as drug targets in neuropsychiatric systemic lupus erythematosus <i>Q&A (5 Mins)</i>	<i>Julius Lindblom (Sweden)</i>
11:50	Discussion and Award (10 Mins)	<i>All</i>
12:00	Poster Viewing and Light Lunch	

*More Posters Available at lupus-academy.org

PLENARY III: DIFFICULT-TO-TREAT LUPUS (LIVE-STREAMED WITH EXTERNAL Q&A)

CEST (Paris, Amsterdam, Berlin) UTC +2: 13:00–15:00 hours

Moderators: Murray Urowitz (Canada) & David Isenberg (UK)		
13:00	APS antibodies: Managing patients when laboratory scenarios don't fit guidelines <i>Q&A and Discussion (15 Mins)</i>	<i>Ricard Cervera (Spain)</i>
13:30	Cardiovascular disease burden in SLE: Risk assessment and management <i>Q&A and Discussion (15 Mins)</i>	<i>Maria Tektonidou (Greece)</i>
14:00	Fatigue in SLE <i>Q&A and Discussion (15 Mins)</i>	<i>Laurent Arnaud (France)</i>
14:30	Infections in SLE <i>Q&A and Discussion (15 Mins)</i>	<i>Sandra Navarra (Philippines)</i>
15:00	Meeting Close	<i>Andrea Doria (Italy) & Eloisa Bonfá (Brazil)</i>